BR9906761A - Formulação de vacina de ácidos nucleicos e acemanano. - Google Patents
Formulação de vacina de ácidos nucleicos e acemanano.Info
- Publication number
- BR9906761A BR9906761A BR9906761-7A BR9906761A BR9906761A BR 9906761 A BR9906761 A BR 9906761A BR 9906761 A BR9906761 A BR 9906761A BR 9906761 A BR9906761 A BR 9906761A
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- formulations
- acemanan
- formulation
- nucleic acids
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 7
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229940023146 nucleic acid vaccine Drugs 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"FORMULAçãO DE VACINA DE áCIDOS NUCLEICOS E ACEMANANO". A presente invenção refere-se ao campo médico, particularmente com o uso de novas formulações de adjuvantes com antígenos de vacina. O objetivo técnico que se busca com a invenção proposta é, precisamente, o desenvolvimento de formulações capazes de potencializar a resposta imune do organismo a vacinas de ácidos nucleicos. Para alcançar este objetivo, foi desenvolvida uma formulação que contém, como componentes fundamentais, o ácido nucleico de vacina e acemanano em proporções adequadas, além de agentes estabilizantes e conservantes. As formulações desta invenção são aplicáveis na indústria farmacêutica como formulações de vacina tanto para uso humano como veterinário.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1998126A CU22740A1 (es) | 1998-09-07 | 1998-09-07 | Formulación de ácidos nucleicos y acemanano |
| PCT/CU1999/000004 WO2000013704A1 (es) | 1998-09-07 | 1999-09-03 | Formulacion de acidos nucleicos y acemanano |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9906761A true BR9906761A (pt) | 2000-10-03 |
Family
ID=5459419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9906761-7A BR9906761A (pt) | 1998-09-07 | 1999-09-03 | Formulação de vacina de ácidos nucleicos e acemanano. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6358933B1 (pt) |
| EP (1) | EP1029549B1 (pt) |
| CN (1) | CN1287493A (pt) |
| AR (1) | AR020403A1 (pt) |
| AT (1) | ATE289518T1 (pt) |
| BR (1) | BR9906761A (pt) |
| CA (1) | CA2308444A1 (pt) |
| CU (1) | CU22740A1 (pt) |
| DE (1) | DE69923829D1 (pt) |
| WO (1) | WO2000013704A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223739B1 (en) | 1995-06-07 | 2007-05-29 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
| US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
| ATE374622T1 (de) * | 1999-11-03 | 2007-10-15 | Powderject Vaccines Inc | Genetische impstoffe mit adjuvans |
| US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
| US20050175625A1 (en) * | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106616A (en) * | 1988-01-14 | 1992-04-21 | Carrington Laboratories, Inc. | Administration of acemannan |
| IL104382A0 (en) * | 1992-01-17 | 1993-05-13 | Solvay Animal Health Inc | Vaccine containing acemannan as an adjuvant |
-
1998
- 1998-09-07 CU CU1998126A patent/CU22740A1/es unknown
-
1999
- 1999-09-03 EP EP99942707A patent/EP1029549B1/en not_active Expired - Lifetime
- 1999-09-03 BR BR9906761-7A patent/BR9906761A/pt not_active IP Right Cessation
- 1999-09-03 CN CN99801915A patent/CN1287493A/zh active Pending
- 1999-09-03 DE DE69923829T patent/DE69923829D1/de not_active Expired - Lifetime
- 1999-09-03 AT AT99942707T patent/ATE289518T1/de not_active IP Right Cessation
- 1999-09-03 CA CA002308444A patent/CA2308444A1/en not_active Abandoned
- 1999-09-03 US US09/530,925 patent/US6358933B1/en not_active Expired - Fee Related
- 1999-09-03 WO PCT/CU1999/000004 patent/WO2000013704A1/es active IP Right Grant
- 1999-09-07 AR ARP990104496A patent/AR020403A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1029549B1 (en) | 2005-02-23 |
| CA2308444A1 (en) | 2000-03-16 |
| DE69923829D1 (de) | 2005-03-31 |
| WO2000013704A1 (es) | 2000-03-16 |
| CN1287493A (zh) | 2001-03-14 |
| CU22740A1 (es) | 2002-02-28 |
| US6358933B1 (en) | 2002-03-19 |
| ATE289518T1 (de) | 2005-03-15 |
| EP1029549A1 (en) | 2000-08-23 |
| AR020403A1 (es) | 2002-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO944799L (no) | Nye biaromatiske propynylforbindelser, farmasöytiske og kosmetiske preparater inneholdende disse, samt deres anvendelser | |
| BR0011116A (pt) | Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas | |
| BR0113822A (pt) | Vacina | |
| BR9815255A (pt) | Toxina de botulismo modificada, vacina oralcontra o botulismo, vacina oral contra umantìgeno selecionado e método para ministraroralmente um agente terapêutico a um animal | |
| PT815235E (pt) | Vacinas para peste | |
| MX9606732A (es) | Compuestos terapeuticos. | |
| BR9906372A (pt) | Composição farmaceutica aquosa para aplicação na mucosa | |
| DK630188A (da) | Laegemidler med indhold af azelastin til anvendelse i naesen og/eller i oejet | |
| BRPI0013010B8 (pt) | formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina | |
| BR0207016A (pt) | Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida | |
| ES2163735T3 (es) | Compuestos biarilos heterociclicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
| BR0208041A (pt) | Interferon beta modificado com imunogenicidade reduzida | |
| BR9906761A (pt) | Formulação de vacina de ácidos nucleicos e acemanano. | |
| BRPI0416376A (pt) | composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes | |
| ES2103116T3 (es) | Nuevos compuestos bi-aromaticos derivados de amida, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
| BR9813514A (pt) | Agente para tratamento de fibras queratìnicas | |
| BR0016304A (pt) | Formulação de solução aquosa de interferon estável, método de preparação e usos para a mesma | |
| BR0207015A (pt) | Eritropoientina modificada (epo) com imunogenicidade reduzida | |
| BR0207905A (pt) | Protamina modificada com imunogenicidade reduzida | |
| BR9808832A (pt) | Formulações de vacina para uso nasofarìngeo, uso mucosal e uso sistêmico | |
| BRPI0409387A (pt) | método para o tratamento de doença de tecido mole em um indivìduo mamìfero, composição farmacêutica, complexo de alvejamento de tecido mole, método para a formação de um complexo, e, kit para uso em um método | |
| BR0208980A (pt) | Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses | |
| BR0306778A (pt) | Derivados de carboxamidina e seu uso no tratamento de doenças vasculares | |
| BR0207020A (pt) | Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida | |
| GB953992A (en) | Vaccine products and method of preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |